

Hydrolysis-free synthesis of 3-aminocoumarins

Amit A. Kudale, Jamie Kendall, C. Chad Warford, Natasha D. Wilkins and
Graham J. Bodwell*

Department of Chemistry, Memorial University, St. John's, NL, Canada A1B 3X7

Received 30 March 2007; revised 11 May 2007; accepted 15 May 2007

Available online 18 May 2007

Abstract—A commonly encountered problem in the synthesis of 3-aminocoumarins is the formation of 3-hydroxycoumarins. A solution to this problem, which involves non-aqueous formation of the 3-aminocoumarin system, is described.
© 2007 Elsevier Ltd. All rights reserved.

The coumarin system is present in a very broad range of natural and non-natural products of biological interest.¹ The 3-aminocoumarin motif, while considerably less prevalent, can nonetheless be found in a number of naturally occurring antibiotics, such as novobiocin **1**,² clorobiocin **2**³ and coumermycin A₁ **3**⁴ (Fig. 1).

Derivatives of 3-aminocoumarins have been found to possess biological activity, including CNS depressant,⁵

antibacterial,⁶ antiallergic⁷ and insect-growth regulatory.⁸ Moreover, 3-aminocoumarin and its derivatives are also known to exhibit interesting photochemical behavior and have found application as fluorescent markers.⁹

Although various methods have been reported for the synthesis of 3-aminocoumarins or related compounds,¹⁰ reproducibility has sometimes been a problem, as




Figure 1. Natural antibiotics containing 3-aminocoumarin.


Keywords: Salicylaldehydes; 3-Acetamidocoumarins; 3-Aminocoumarins.

* Corresponding author. Tel.: +1 709 737 8406; fax: +1 709 737 3702; e-mail: gbodywell@mun.ca

experienced by us and others.¹¹ The final step of these syntheses is typically the hydrolysis of a 3-acetamidocoumarin, which can result in the formation of a 3-hydroxycoumarin, both under acidic and basic conditions.¹² Herein, we report an efficient and convenient synthesis of 3-aminocoumarin and several derivatives bearing a substituent on the carbocyclic ring.


For the parent 3-aminocoumarin (**7a**), the synthesis commenced with the conversion of commercially available (or easily prepared from salicylaldehyde and *N*-acetylglucine¹³) 3-acetamidocoumarin (**5a**) to Boc-protected 3-aminocoumarin (**6a**) using the method of Burk and Allen¹⁴ in 94% yield. This one-pot procedure, which was originally developed for amino acids, involves an acylation–deacylation sequence in which an *N*-acetyl compound is reacted with di-*t*-butyl dicarbonate in the presence of DMAP to give an imide, followed by reaction with hydrazine hydrate to remove the acetyl group. The resulting *t*-butyl carbamate (**6a**) could then be easily deprotected to give 3-aminocoumarin (**7a**) in high yield (99%) under anhydrous conditions through the action of 15% TFA/CHCl₃ (Scheme 1). In our hands, this method has proved to be very reproducible and we have prepared up to 15 g of 3-aminocoumarin in a single run.

For the synthesis of substituted 3-aminocoumarins, suitably substituted 3-acetamidocoumarins (**5**) were required. Being commercially unavailable, it was envisaged that these compounds could be prepared from the corresponding salicylaldehyde and *N*-acetylglucine.¹³ Since the yield for parent 3-acetamidocoumarin (**5a**) is low (27%) using this method, efforts were made to optimize the reaction conditions for the conversion of salicylaldehyde (**4a**) into compound **5a**. After varying reaction time, temperature, number of equivalents of *N*-acetylglucine and sodium acetate, it was found that the use of 4.0 equiv of sodium acetate and 1.0 equiv of *N*-acetylglucine at 110–120 °C for 3.5 h gave the best yield (46%) for the parent 3-acetamidocoumarin (**5a**). Employing the same reaction conditions for a series of substituted salicylaldehydes (commercially available or easily prepared by known formylation protocols¹⁵) afforded the corresponding 3-acetamidocoumarins (**5b–i**) (Table 1). The yields for these reactions were variable. Poor yields were obtained when an electron-donating group was situated *para* to the aldehyde function of the starting salicylaldehyde (Table 1, entries 6 and 8). Otherwise, the yields ranged from 40% to 69%. When



Scheme 1. General synthesis of 3-aminocoumarins **7**.

Table 1. Condensation of salicylaldehydes with *N*-acetylglucine



Entry	R	Product	Yield ^a (%)
1	H	5a	46
2	6-Br	5b	69
3	6-Me	5c	42
4	6-NO ₂	5d	69
5	6-OMe	5e	40
6	7-OMe	5f	20
7	8-OMe	5g	69
8	7-OAc	5h	21 ^b
9	5,6-Benzo	5i	63

^a Isolated yield, >95% purity by ¹H NMR analysis.


^b 4-HOC₆H₄CHO was the starting material in this reaction. The hydroxyl group undergoes acetylation under the reaction conditions.

the starting material was 4-hydroxysalicylaldehyde (Table 1, entry 8), *O*-acylation took place, giving 7-acetoxy-3-acetamidocoumarin (**5h**) as the product.

The next step involved conversion of the acetamide to a *t*-butyl carbamate. Burk and Allen's one-pot protocol was then employed to afford the Boc-protected 3-aminocoumarins (**6b–i**) (Table 2). Under these conditions, the acetoxy group in compound **5h** was converted back to a hydroxy group (Table 2, entry 8). For the most part, the yields were high. As above, the yields of the products with donor groups at the 7-position (Table 2, entries 6 and 8) were comparatively low.

Removal of the Boc-group using 15% TFA/CHCl₃ then afforded the 3-aminocoumarins (**7b–i**) in generally very good yields (58–96%) (Table 3). In no case was any 3-hydroxycoumarin detected. Clearly, the use of a *t*-butoxycarbonyl protecting group is crucial because it can be removed under anhydrous conditions. The optimal reaction times for preparing the desired 3-amino-

Table 2. Conversion of 3-acetamidocoumarins (**5**) into Boc-protected 3-aminocoumarins (**6**)




Entry	R	Product	Yield ^a (%)
1	H	6a	94
2	6-Br	6b	87
3	6-Me	6c^b	90
4	6-NO ₂	6d	93
5	6-OMe	6e^b	93
6	7-OMe	6f^b	58
7	8-OMe	6g^b	92
8	7-OH	6h^b	50
9	5,6-Benzo	6i^b	95

^a Isolated yield, >95% purity by ¹H NMR analysis.

^b New compound. See Ref. 16.


Table 3. Removal of the Boc group



Entry	R	Product	Yield ^a (%)
1	H	7a	99
2	6-Br	7b	67
3	6-Me	7c	96
4	6-NO ₂	7d	89
5	6-OMe	7e	95
6	7-OMe	7f	58 ^b
7	8-OMe	7g	80
8	7-OH	7h	96
9	5,6-Benzo	7i	65

^a Isolated yield, >95% purity by ¹H NMR analysis.

^b 37% **6f** recovered after 3 h.

Scheme 2. Formation of 3-trifluoroacetamidocoumarin **8**.

coumarins were found to be generally between 3 and 4.5 h at room temperature. Longer reaction times resulted in a decrease in the yields of desired 3-aminocoumarins and the formation of the corresponding 3-trifluoroacetamidocoumarin (**8**) (Scheme 2). For the parent system, 3-trifluoroacetamidocoumarin (**8a**)¹⁷ was isolated in 14% yield after a reaction time of 31 h. Yields as high as 35–45% were obtained for substrates **6d** and **6e** when the reaction was run for 27 h. Evidently, the 3-aminocoumarin, once formed, is acylated by the solvent. Indeed, stirring pure 3-aminocoumarin (**7a**) in 15%. TFA/CHCl₃ at room temperature resulted in the slow formation of compound **8a** (tlc analysis). After stirring for 7 days, roughly equivalent amounts of compounds **7a** and **8a** were present in solution (tlc analysis) and, after a further day's reaction at reflux, trifluoroacetamidocoumarin (**8a**) was isolated in 68% yield.

In conclusion, we have developed a hydrolysis-free method for the synthesis of 3-aminocoumarins. It can be used to prepare multigram quantities of various 3-aminocoumarins and does not result in the formation of any 3-hydroxycoumarins.

Acknowledgments

The Natural Sciences and Engineering Research Council (NSERC) of Canada and AnorMED Inc are gratefully acknowledged for financial support of this work.

Supplementary data

Experimental procedures, characterization data and ¹H and ¹³C NMR spectra for individual compounds. Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.tetlet.2007.05.088.

References and notes

- (a) Mali, R. S.; Yadav, V. J. *Synthesis* **1977**, 464–465; (b) Narasimhan, N. S.; Mali, R. S.; Barve, M. V. *Synthesis* **1979**, 906–909; (c) Schönberg, A.; Latif, N. *J. Am. Chem. Soc.* **1954**, *76*, 6208; (d) Baraldi, P. G.; Manfredini, S.; Simoni, D.; Tabrizi, M. A.; Baljarini, J.; Clercq, E. D. *J. Med. Chem.* **1992**, *35*, 1877–1882; (e) Kashman, Y.; Gustafson, K. R.; Fuller, R. W.; Cardellina, J. H.; McMahon, J. B.; Currens, M. J.; Buckheit, R. W.; Hughes, S. H.; Cragg, G. M.; Boyd, M. R. *J. Med. Chem.* **1992**, *35*, 2735–2743; (f) Patil, A. D.; Freyer, A. J.; Eggleston, D. S.; Haltiwanger, R. C.; Bean, M. F.; Taylor, P. B.; Caranfa, M. J.; Breen, A. L.; Bartus, H. R.; Johnson, R. K.; Hertzberg, R. P.; Westley, J. W. *J. Med. Chem.* **1993**, *36*, 4131–4138; (g) Bhalla, M.; Naithani, P. K.; Kumar, A.; Bhalla, T. N.; Shanker, K. *Indian J. Chem. B* **1992**, *31*, 183–186; (h) Nagesam, M.; Raju, M. S.; Raju, K. M. *J. Indian Chem. Soc.* **1987**, *64*, 418–419; (i) Nagesam, M.; Raju, K. M.; Raju, M. S. *J. Indian Chem. Soc.* **1988**, *65*, 380–382; (j) Perrella, F. W.; Chen, S.; Behrens, D. L.; Kaltenbach, R. F.; Seitz, S. P. *J. Med. Chem.* **1994**, *37*, 2232–2237; (k) Thakur, R. S.; Bagadia, S. C.; Sharma, M. L. *Experientia* **1978**, *34*, 158–159; (l) Hishmat, O. H.; Miky, J. A. A.; Farrag, A. A.; Fadl-Allah, E. M. *Arch. Pharmacol. Res.* **1989**, *12*, 181–185.
- (a) Raad, I.; Darouiche, R.; Hachem, R.; Sacilowski, M.; Bodey, G. P. *Antimicrob. Agents Chemother.* **1995**, *39*, 2397; (b) Raad, I. I.; Hachem, R. Y.; Abi-said, D.; Rolston, K. V. I.; Whimbey, E.; Buzaid, A. C.; Legha, S. *Cancer* **1998**, *82*, 403; (c) Vaterlaus, B. P.; Kiss, J.; Spiegelberg, H. F. *Helv. Chim. Acta* **1964**, *47*, 381–390.
- (a) Ninet, L.; Benazet, F.; Charpentie, Y.; Dubost, M.; Florent, J.; Mancy, D.; Preud'homme, J.; Threlfall, T. L.; Vuillemin, B.; Wright, D. E.; Abraham, A.; Cartier, M.; Chezelles, M.; Godard, D.; Theilleux, J. *C.R. Acad. Sci. Paris (C)* **1972**, *275*, 455–458; (b) Coulson, C. J.; Smith, V. J. *J. Pharm. Sci.* **1980**, *69*, 799–801; (c) Cejka, K.; Holubova, I.; Hubáček, J. *J. Mol. Gen. Genetics* **1982**, *186*, 153–155; (d) Galm, U.; Heller, S.; Shapiro, S.; Page, M.; Li, S.-M.; Heide, L. *Antimicrob. Agents Chemother.* **2004**, *48*, 1307–1312.
- (a) Kawaguchi, H.; Tsukiura, H.; Okanishi, M.; Miyaki, T.; Ohmori, T.; Fujisawa, K.; Koshiyama, H. *J. Antibiot.* **1965**, *18*, 1–10; (b) Kawaguchi, H.; Naito, T.; Tsukiura, H. *J. Antibiot.* **1965**, *18*, 11–25.
- Kulkarni, Y. D.; Srivastava, D.; Bishnoi, A.; Dua, P. R. *J. Indian Chem. Soc.* **1996**, *73*, 173–175.
- (a) Rodighiero, G.; Antonello, C. *Bull. Chim. Farm.* **1958**, *97*, 592–601; (b) Krishna Mohan Rao, K. S. R.; Subba Rao, N. V. *Proc. Indian Acad. Sci.* **1968**, *67*, 42–49; (c) Krishna Mohan Rao, K. S. R.; Subba Rao, N. V. *Indian J. Chem.* **1965**, *3*, 522–524; (d) El-Naggar, A. M.; Ahmed, F. S. M.; Abd El-Salam, A. M.; Radi, M. A.; Latif, M. S. A. *J. Heterocycl. Chem.* **1981**, *18*, 1203–1207; (e) Okumura, K.; Ashino, K.; Okuda, T. *J. Pharm. Soc. Jpn.* **1961**, *81*, 1482–1488.
- Connor, D. T. U.S. Patent, 126,4,287, 1981.

8. Shyamala, B. S.; Ananthalakshmi, P. V.; Raju, V. J. T.; Nagaraja Rao, P.; Reddy, P. U. M. *Biometals* **1992**, *5*, 23–27.
9. (a) Kokotos, G.; Tzougraki, C. *Int. J. Peptide Protein Res.* **1986**, *28*, 186–191; (b) Charitos, C.; Tzougraki, C.; Kokotos, G. *J. Peptide Res.* **2000**, *56*, 373–381; (c) Chaurasia, C.; Kauffman, J. M. *J. Heterocycl. Chem.* **1990**, *27*, 727; (d) Dorlars, A.; Schellhammer, C.; Schroeder, J. *Angew. Chem., Int. Ed. Engl.* **1975**, *14*, 665–679; (e) Subba Rao, R. V.; Krishnamurthy, M.; Dogra, S. *J. Photochem.* **1986**, *34*, 55–61; (f) Dzubenko, M. I.; Maslov, V. V.; Naumenko, I. G.; Nikitchenko, V. M.; Pelipenko, V. P. *Opt. Spektrosk.* **1978**, *45*, 814–816; (g) Kokotos, G.; Tzougraki, C. *J. Chem. Soc., Perkin Trans. 2* **1991**, 495–499; (h) Christie, R. M.; Lui, C.-H. *Dyes Pigments* **1999**, *42*, 85–93.
10. (a) Linch, F. W. *J. Chem. Soc.* **1912**, *101*, 1755–1759; (b) Linch, F. W. *J. Chem. Soc.* **1912**, *101*, 1759–1765; (c) Dakin, H. D. *J. Biol. Chem.* **1929**, *82*, 439; (d) Chakravarti, D.; Das, R. *J. Indian Chem. Soc.* **1971**, *48*, 371–374; (e) Chakravarti, D.; Das, R. *J. Indian Chem. Soc.* **1971**, *48*, 375–380; (f) Toplak, R.; Svete, J.; Stanovnik, B.; Grdadolnik, S. G. *J. Heterocycl. Chem.* **1999**, *36*, 225–234; (g) Fajgelj, S.; Stanovnik, B.; Tišler, M. *J. Heterocycl. Chem.* **1990**, *27*, 1873–1874; (h) Tripathy, P. K.; Mukerjee, A. K. *Indian J. Chem. B* **1987**, *26*, 61–62; (i) Bonsignore, L.; Loy, G. *J. Heterocycl. Chem.* **1998**, *35*, 117–119; (j) Valizadeh, H.; Shokravi, A. *Heterocycl. Commun.* **2004**, *10*, 475–478; (k) Ornik, B.; Stanovnik, B.; Tišler, M. *J. Heterocycl. Chem.* **1992**, *29*, 1241–1244; (l) Khoo, L. E. *Synth. Commun.* **1999**, *29*, 2533–2538; (m) Kokotos, G.; Tzougraki, C. *J. Heterocycl. Chem.* **1986**, *23*, 87–92; (n) Beccalli, E. M.; Contini, A.; Trimarco, P. *Eur. J. Org. Chem.* **2003**, 3976–3984; (o) Domschke, G. *Z. Chem.* **1962**, *2*, 114; (p) Kočevar, M.; Polanc, S.; Tišler, M.; Verček, B. *Heterocycles* **1990**, *30*, 227–230; (q) Shin, C.; Nakajima, Y.; Haga, T.; Sato, Y. *Bull. Chem. Soc. Jpn.* **1986**, *59*, 3917–3923; (r) Ito, K.; Higuchi, Y.; Tame, C.; Hariya, J. *Heterocycles* **1993**, *35*, 937–947.
11. (a) Kendall, J. *M.Sc. Dissertation*, Memorial University of Newfoundland, 2002; (b) Trivedi, K.; Sethna, S. *J. Org. Chem.* **1960**, *25*, 1817–1819; (c) Chakravarti, D.; Dutta, S. P.; Mitra, A. K. *Curr. Sci.* **1965**, 177.
12. Khan, M. A.; Lucia, M. *Bull. Soc. Quim. Peru* **1979**, *45*, 42–45.
13. Shaw, K. N. F.; McMillan, A.; Armstrong, M. D. *J. Org. Chem.* **1956**, *21*, 601–604.
14. Burk, M. J.; Allen, J. G. *J. Org. Chem.* **1997**, *62*, 7054–7057.
15. (a) Duff, C. J. *J. Chem. Soc.* **1941**, 547; (b) Hofsløkken, N. U.; Skattebøl, L. *Acta Chem. Scand.* **1999**, *53*, 258–262.
16. Compound **6c**: Mp = 133–134 °C; δ_{H} (CDCl₃, 500 MHz) = 8.22 (s, 1H), 7.40 (s, 1H), 7.24 (m, 1H), 7.20 (m, 2H), 2.39 (s, 3H), 1.53 (s, 9H) ppm; δ_{C} (CDCl₃, 125 MHz) = 159.0, 152.7, 147.9, 134.9, 130.2, 127.4, 124.7, 120.6, 120.0, 116.2, 81.8, 28.4, 21.1 ppm; IR ν = 3407 (m), 1717 (m), 1707 (m), 1632 (s), 1616 (s), 1581 (s), 1510 (m) cm⁻¹; MS m/z (%) = 175 (100, M⁺); HRMS calcd for C₁₅H₁₇NO₄ 275.1158, found 275.1149. Compound **6e**: Mp = 164–165 °C (EtOAc/hexanes); δ_{H} (CDCl₃, 500 MHz) = 8.24 (s, 1H), 7.42 (s, 1H), 7.23 (d, J = 9.0 Hz, 1H), 6.97 (dd, J = 9.2, 2.6 Hz, 1H), 6.90 (d, J = 2.7 Hz, 1H), 3.83 (s, 3H), 1.54 (s, 9H) ppm; δ_{C} (CDCl₃, 125 MHz) = 158.9, 156.8, 152.7, 144.2, 125.2, 120.8, 120.4, 117.5, 116.8, 109.8, 82.0, 56.0, 28.4 ppm; IR ν = 3416 (m), 1729 (s), 1693 (b), 1583 (s) cm⁻¹; MS m/z (%) = M⁺ not obs., 191 (100); HRMS calcd for C₁₅H₁₇NO₅ 291.1107, found 291.1101. Compound **6f**: Mp = 117–118 °C (EtOAc/hexanes); δ_{H} (CDCl₃, 500 MHz) = 8.23 (s, 1H), 7.35 (d, J = 8.7 Hz, 1H), 7.29 (s, 1H), 6.86 (dd, J = 8.6, 2.6 Hz, 1H), 6.81 (d, J = 1.8 Hz, 1H), 3.85 (s, 3H), 1.53 (s, 9H) ppm; δ_{C} (CDCl₃, 125 MHz) = 161.0, 159.1, 152.8, 151.2, 128.3, 122.4, 121.4, 113.5, 113.2, 100.9, 81.7, 55.9, 28.4 ppm; IR ν = 3318 (m), 1726 (m), 1699 (s), 1631 (m), 1613 (s), 1575 (m), 1524 (s) cm⁻¹; MS m/z (%) = M⁺ not obs., 191 (100); HRMS calcd for C₁₅H₁₇NO₅ 291.1107, found 291.1099. Compound **6g**: Mp = 97–99 °C (EtOAc/hexanes); δ_{H} (CDCl₃, 500 MHz) = 8.25 (s, 1H), 7.43 (s, 1H), 7.22–7.19 (m, 1H), 7.04 (d, J = 7.0 Hz, 1H), 6.97 (d, J = 8.1 Hz, 1H), 3.96 (s, 3H), 1.53 (s, 9H) ppm; δ_{C} (CDCl₃, 125 MHz) = 158.3, 152.7, 147.2, 139.2, 125.1, 125.1, 121.0, 120.6, 119.1, 111.3, 81.9, 56.4, 28.4 ppm; IR ν = 3318 (m), 1729 (s), 1703 (s), 1580 (m), 1532 (m) cm⁻¹; MS m/z (%) = M⁺ not obs., 191 (100); HRMS calcd for C₁₅H₁₇NO₅ 291.1107, found 291.1110. Compound **6h**: Mp = 177–178 °C (CH₂Cl₂/hexanes); δ_{H} (CDCl₃, 500 MHz) = 8.24 (s, 1H), 7.32 (d, J = 7.8 Hz, 1H), 7.27 (s, 1H), 6.88 (d, J = 1.5 Hz, 1H), 6.83 (dd, J = 8.2, 2.6 Hz, 1H), 6.42 (s, 1H), 1.53 (s, 9H) ppm; δ_{C} (CDCl₃, 125 MHz) = 159.6, 157.8, 152.9, 151.1, 128.7, 122.4, 122.0, 114.3, 113.4, 103.2, 82.0, 28.4 ppm; IR ν = 3317 (m), 17039 (s), 1681 (s), 1633 (s), 1608 (s), 1535 (s), 1512 (s) cm⁻¹; MS m/z (%) = M⁺ not obs., 177 (100); HRMS calcd for C₁₄H₁₅NO₅ 277.0950, found 277.0951. Compound **6i**: Mp = 192–194 °C (EtOAc/hexanes); δ_{H} (CDCl₃, 500 MHz) = 9.10 (s, 1H), 8.35 (d, J = 7.8 Hz, 1H), 7.90–7.85 (m, 2H), 7.65–7.64 (m, 1H), 7.58–7.55 (m, 1H), 7.49 (s, 1H), 7.44 (d, J = 9.4 Hz, 1H), 1.59 (s, 9H) ppm; δ_{C} (CDCl₃, 125 MHz) = 158.8, 152.8, 148.3, 130.9, 130.3, 129.2, 129.0, 127.8, 126.3, 124.8, 122.6, 116.8, 116.6, 114.6, 82.0, 28.5; IR ν = 3316 (m), 1701 (s), 1575 (s), 1522 (s) cm⁻¹; MS m/z (%) = M⁺ not obs., 211 (100); HRMS calcd for C₁₈H₁₇NO₄ = 311.1158, found = 311.1149.
17. Compound **8a**: Mp = 132–133 °C (EtOAc/hexanes); δ_{H} (CDCl₃, 500 MHz) = 8.81 (s, 1H), 8.70 (s, 1H), 7.59–7.54 (m, 2H), 7.40–7.36 (m, 2H) ppm; δ_{C} (CDCl₃, 125 MHz) = 158.1, 155.7 (q, $J_{\text{C-F}}$ = 39.1 Hz), 150.7, 131.3, 128.5, 126.5, 125.8, 122.2, 119.0, 116.9, 115.3 (q, $J_{\text{C-F}}$ = 288.4 Hz) ppm; IR ν = 3298 (m), 1735 (m), 1694 (s), 1626 (b), 1607 (s), 1555 (s) cm⁻¹; HRMS calcd for C₁₁H₆F₃NO₃ 257.0300, found 257.0298.